ArticleVeterinary clinical pathology2026
Codocytosis in the Dog: 345 Cases (2020-2022).
Article in Veterinary clinical pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCodocytes, or target cells, are a morphologic variation of erythrocytes characterized by increased membrane surface area relative to volume. In dogs, codocytosis is frequently noted on blood smear evaluation, but its clinical significance remains poorly understood.
objectivesTo characterize the clinical conditions associated with codocytosis in dogs and assess relationships between codocyte severity and hematologic, biochemical, and diagnostic findings.
methodsA retrospective descriptive study was conducted on 345 dogs from a veterinary teaching hospital from September 2020 through October 2022. Dogs were included if their CBC report described codocytosis graded as ≥ 2+. Data collected included CBC results, serum biochemistry, clinical diagnoses, and current medications. Codocytosis was graded semi-quantitatively (2+ to 4+). Statistical comparisons were made using chi-square tests.
resultsCodocytosis ≥ 2+ was identified in 2.5% of 14 010 canine CBCs during the study. The majority (81.4%) had 2+ codocytes. There were no significant differences in anemia, macrocytosis, or regeneration across grades. Dogs with 3+ or 4+ codocytosis had significantly higher alanine transferase (ALT) activity and were more frequently diagnosed with hepatobiliary (p = 0.006) and gastrointestinal (p = 0.009) diseases. Endocrine disease, particularly diabetes mellitus was also frequently observed. Antibiotic use was significantly associated with higher codocyte grades (p < 0.001), though no causation was identified.
conclusionsCodocytosis in dogs is not primarily associated with anemia or regeneration, but rather appears more frequently in diseases affecting hepatobiliary, gastrointestinal, and endocrine systems. These findings suggest a multifactorial pathogenesis likely involving altered lipid metabolism and membrane remodeling. Recognition of codocytosis may provide insight into systemic disease processes in canine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.